title: Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
abstract: OBJECTIVE
  The histological differential diagnosis between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) is not always straightforward. The aim of the present study was to search for new immunohistochemical markers to distinguish EM from RMH.
  
  
  METHODS
  We evaluated and compared the expression of apoptosis-related genes in EM and RMH by real-time RT-PCR array analysis followed by clustering of significant gene expression. Immunohistochemical staining and statistical analysis of Noxa expression in 81 cases of EM and 55 cases of RMH were performed and compared with the utility of other previously reported antibodies such as Desmin, EMA, GLUT-1, IMP-3 and CD146.
  
  
  RESULTS
  Noxa mRNA expression levels were found to be increased in EM when compared to RMH by RT-PCR array analysis. In the immunohistochemical analysis, Noxa showed sensitivity of 69.0%, specificity of 93.6% and positive predictive value of 93.0% as a positive marker of EM in distinguishing it from RMH, and these values were almost similar to IMP-3.
  
  
  CONCLUSIONS
  Noxa is a marker with relatively high specificity, and can be used to distinguish EM from RMH. It would be a valuable addition to the current antibody panel used for the differential diagnosis of EM and RMH.
authors.affiliation: Department of Pathology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Kushitani
authors.forename: Vishwa Jeet
authors.initials: VJ
authors.lastname: Amatya
authors.forename: Amany Sayed
authors.initials: AS
authors.lastname: Mawas
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Miyata
authors.forename: Morihito
authors.initials: M
authors.lastname: Okada
authors.forename: Yukio
authors.initials: Y
authors.lastname: Takeshima
mesh_terms: D000906:Antibodies; D017209:Apoptosis / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000032:analysis*; D045744:Cell Line, Tumor; D003893:Desmin / Q000032:analysis / Q000276:immunology; D003937:Diagnosis, Differential; D005260:Female; D020869:Gene Expression Profiling; D051272:Glucose Transporter Type 1 / Q000032:analysis / Q000276:immunology; D006801:Humans; D006965:Hyperplasia / Q000175:diagnosis*; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000648:ultrastructure; D008654:Mesothelioma / Q000175:diagnosis* / Q000648:ultrastructure; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D018396:Mucin-1 / Q000032:analysis / Q000276:immunology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis / Q000235:genetics* / Q000276:immunology*; D060888:Real-Time Polymerase Chain Reaction; D012680:Sensitivity and Specificity
chemical_list: D000906:Antibodies; D014408:Biomarkers, Tumor; D003893:Desmin; D051272:Glucose Transporter Type 1; D018396:Mucin-1; C498702:PMAIP1 protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; C495677:SLC2A1 protein, human